Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
Ajay Abraham, … , Victor M. Darley-Usmar, Ravi Bhatia
Ajay Abraham, … , Victor M. Darley-Usmar, Ravi Bhatia
Published June 10, 2019
Citation Information: J Clin Invest. 2019;129(7):2685-2701. https://doi.org/10.1172/JCI127080.
View: Text | PDF
Research Article Hematology Oncology

SIRT1 regulates metabolism and leukemogenic potential in CML stem cells

  • Text
  • PDF
Abstract

Chronic myeloid leukemia (CML) results from hematopoietic stem cell transformation by the BCR-ABL kinase. Despite the success of BCR-ABL tyrosine kinase inhibitors (TKIs) in treating CML patients, leukemia stem cells (LSCs) resist elimination and persist as a major barrier to cure. Previous studies suggest that overexpression of the sirtuin 1 (SIRT1) deacetylase may contribute to LSC maintenance in CML. Here, by genetically deleting SIRT1 in transgenic CML mice, we definitively demonstrated an important role for SIRT1 in leukemia development. We identified a previously unrecognized role for SIRT1 in mediating increased mitochondrial oxidative phosphorylation in CML LSCs. We showed that mitochondrial alterations were kinase independent and that TKI treatment enhanced inhibition of CML hematopoiesis in SIRT1-deleted mice. We further showed that the SIRT1 substrate PGC-1α contributed to increased oxidative phosphorylation and TKI resistance in CML LSCs. These results reveal an important role for SIRT1 and downstream signaling mechanisms in altered mitochondrial respiration in CML LSCs.

Authors

Ajay Abraham, Shaowei Qiu, Balu K. Chacko, Hui Li, Andrew Paterson, Jianbo He, Puneet Agarwal, Mansi Shah, Robert Welner, Victor M. Darley-Usmar, Ravi Bhatia

×

Figure 8

SIRT1 and tyrosine kinase inhibition result in dual inhibition of mitochondrial respiration and glycolysis in human CML stem/progenitor cells.

Options: View larger image (or click on image) Download as PowerPoint
SIRT1 and tyrosine kinase inhibition result in dual inhibition of mitoch...
(A and B) OCR measurements in c-Kit+ cells from CML mice treated with NIL or vehicle (n = 7 each) for 2 weeks. (C and D) OCR (C) and ECAR (D) measurements in CP CML CD34+ cells (n = 4) after exposure to NIL (1 μM), TV39OH (5 μM), combination, or vehicle for 3 hours. (E–G) CML CD34+CD38–CFSEhi cells (n = 4) were exposed to NIL (1 μM) TV39OH (5 μM), combination, or vehicle for 72 hours. (E) Representative flow cytometry plots showing annexin V and CFSE expression. (F) Representative flow cytometry histograms showing CFSE fluorescence in CD34+CD38–CFSEhi cells. (G) Proliferation index measured based on analysis of CFSE fluorescence in CD34+CD38–CFSEhi cells. (H) Apoptosis in CD34+CD38–CFSEhi cells measured by annexin V labeling. (I) CP CML CD34+CD38– cells (n = 3) were exposed to vehicle, NIL (1 μM), TV39OH (5 μM), or combination for 72 hours and plated in methylcellulose progenitor culture. Colonies were enumerated after 14 days. Error bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, ordinary 1-way ANOVA (G–I) or 2-way ANOVA (B–D) correcting for multiple comparisons by controlling the FDR using the 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts